Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Add filters

Document Type
Year range
International Journal of Research in Pharmaceutical Sciences ; 11(Special Issue 1):1841-1845, 2020.
Article in English | EMBASE | ID: covidwho-1160270


The outbreak of novel coronavirus disease was first reported in China in December 2019, and WHO declared the coronavirus pandemic on 11 March 2020. Since then, all the continents have observed a fast-growing upward trend in number of confirmed cases. During the epidemics, Sexual and reproductive health (SRH) and rights became a monumentous public health issue. The novel coronavirus (SARS-CoV-2) is new to humans and there is only some experimental data available to describe the sexual and reproductive health (SRH) effects of COVID-19 disease, including clinical appearance and consequences of COVID-19 infection during birth, or for people with STI (sexually transmitted infections) or HIV-related immunosuppression. We should not neglect the bearings at the level of the health system and delays or interludes in the routine availability of SRH facilities outside the therapeutic reach of SRH, such as pre-and postnatal tests, safe abortion, contraception, HIV/AIDS, and sexually transmitted infections. In addition, other factors warrant con-sideration, such as the possible rise in gender-based violence and domes-tic abuse and the consequences of COVID-19-related stigma and prejudice and their effect on SRH customers and health care providers. Therefore, the research community has an immediate requirement for the creation of all-inclusive clinical, epidemiological, and psycho-social behavioral ties between COVID-19 and SRH and the effects of rights. A comprehensive systematic literature search of the databases of PubMed, Web of Science, Embase, Medline, Cochrane and MedRxiv, was carried out.